Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA‐REG OUTCOME® trial
Abstract Aims/Introduction In the EMPA‐REG OUTCOME® trial, empagliflozin added to standard of care improved clinically relevant kidney outcomes by 39%, slowed progression of chronic kidney disease, and reduced albuminuria in patients with type 2 diabetes and established cardiovascular disease. This...
Main Authors: | Takashi Kadowaki, Masaomi Nangaku, Stefan Hantel, Tomoo Okamura, Maximilian vonEynatten, Christoph Wanner, Audrey Koitka‐Weber |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-05-01
|
Series: | Journal of Diabetes Investigation |
Subjects: | |
Online Access: | https://doi.org/10.1111/jdi.12971 |
Similar Items
-
Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA‐REG OUTCOME
by: Pierpaolo Pellicori, et al.
Published: (2020-12-01) -
Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA‐REG OUTCOME trial
by: Subodh Verma, et al.
Published: (2021-08-01) -
Empagliflozin reduced long-term HbA1c variability and cardiovascular death: insights from the EMPA-REG OUTCOME trial
by: Antonio Ceriello, et al.
Published: (2020-10-01) -
Cost‐effectiveness of empagliflozin in the UK in an EMPA‐REG OUTCOME subgroup with type 2 diabetes and heart failure
by: Odette S. Reifsnider, et al.
Published: (2020-12-01) -
Following the results of the EMPA-REG OUTCOME trial with empagliflozin, is it possible to speak of a class effect?
by: Ampudia-Blasco FJ, et al.
Published: (2017-01-01)